The document aims to clarify regulation rules of minimal manipulation with human cell and tissue products. The FDA’s guidance documents normally do not “establish legally enforceable responsibilities” but “describe the agency’s current thinking on a topic and should be viewed only as recommendations,” the agency said.
HCT/Ps are “intended for implantation, transplantation, infusion or transfer into a human recipient,” according to the FDA’s definition. The agency clarified that hospitals and labs do not have to register human cell and tissue-based products “that are used solely for nonclinical scientific or educational purposes.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
